Abstract:<p>Phosphate binding drugs are crucial in reducing blood phosphate concentrations in individuals with end-stage renal disease (ESRD) to prevent hyperphosphatemia. While many phosphate binding drugs exist, lanthanum carbonate [La2(CO3)3, LaC] has been reported to be better tolerated than previously used calcium- and aluminum-based phosphate binders. However, since large doses ranging up to 3750 mg LaC/day is orally administered to ESRD patients, concerns have been raised as to whether chronic exposure to … Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.